{
    "pmcid": "8951411",
    "qa_pairs": {
        "How do multivalent nanobodies enhance their neutralization potency?": [
            "By linking multiple nanobody units to increase avidity",
            "By increasing their molecular weight to improve stability",
            "By binding to the host cell membrane directly",
            "By altering the spike protein's genetic sequence"
        ],
        "What advantage do nanobodies have over conventional antibodies in targeting the SARS-CoV-2 spike protein?": [
            "They are smaller and more stable, allowing access to cryptic epitopes",
            "They have a higher molecular weight, enhancing binding strength",
            "They can be produced more rapidly in bacterial systems",
            "They are less specific, allowing broader immune responses"
        ],
        "What computational tools are used to explore nanobody-spike interactions?": [
            "Molecular dynamics simulations and mutational scanning",
            "Genomic sequencing and phylogenetic analysis",
            "Flow cytometry and ELISA assays",
            "CRISPR-Cas9 gene editing and RNA sequencing"
        ],
        "What is a key strategy for designing nanobodies to resist escape mutations in SARS-CoV-2 variants?": [
            "Targeting conserved regions less prone to mutations",
            "Increasing the size of the nanobody to cover more epitopes",
            "Focusing on the variable regions of the spike protein",
            "Reducing the binding affinity to allow for flexibility"
        ],
        "What is the primary function of the SARS-CoV-2 spike protein in viral entry?": [
            "Binding to the ACE2 receptor",
            "Facilitating viral replication",
            "Inhibiting host immune response",
            "Promoting viral assembly"
        ]
    }
}